| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | 567,833 | 648,348 | 586,350 | 643,331 |
| Interest expense, net | 958 | 1,070 | 909 | 960 |
| Net loss | -568,791 | -649,418 | -587,259 | -644,291 |
| Net loss per share, basic | -0.03 | -0.034 | -0.03 | -0.04 |
| Net loss per share, diluted | -0.03 | -0.034 | -0.03 | -0.04 |
| Weighted average number of common shares outstanding during the period- basic | 18,579,776 | 18,326,587 | 18,522,295 | 17,970,120 |
| Weighted average number of common shares outstanding during the period- diluted | 18,579,776 | 18,326,587 | 18,522,295 | 17,970,120 |
RetinalGenix Technologies Inc. (RTGN)
RetinalGenix Technologies Inc. (RTGN)